Conmed (CNMD) Tops Q1 EPS by 8c; Hikes FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
CONMED Corporation Announces First Quarter 2022 Financial Results
May 4, 2022 4:05 PM EDTLARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2022.
First Quarter 2022 Highlights
Sales of $242.3 million increased 4.1% year over year as reported and 4.3% in constant currency. Domestic revenue increased 5.9% year over year. International revenue increased 2.2% year over year as reported and 2.6% in constant currency. Diluted net earnings per share (GAAP) were $0.47, an increase of 51.6% over the first quarter of 2021. Adjusted diluted net earnings per share(1) were $0.70, an... More